Edition:
United Kingdom

Agile Therapeutics Inc (AGRX.OQ)

AGRX.OQ on NASDAQ Stock Exchange Global Market

4.95USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$4.95
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
51,505
52-wk High
$7.03
52-wk Low
$1.82

Chart for

About

Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as... (more)

Overall

Beta: 2.07
Market Cap(Mil.): $180.60
Shares Outstanding(Mil.): 34.14
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Agile Therapeutics Q3 loss per share $0.22

* Agile therapeutics reports third quarter 2017 financial results

06 Nov 2017

BRIEF-‍Caxton Corp reports 5.3 pct passive stake in Agile Therapeutics Inc

* ‍Caxton Corp reports 5.3 percent passive stake in Agile Therapeutics Inc as on August 9, 2017 - SEC filing​ Source text (http://bit.ly/2vKGGOo) Further company coverage:

18 Aug 2017

BRIEF-Agile Therapeutics announces proposed offering of common stock

* Agile Therapeutics announces proposed offering of common stock

02 Aug 2017

BRIEF-Agile Therapeutics reports second quarter 2017 financial results

* Q2 earnings per share view $-0.28 -- Thomson Reuters I/B/E/S

28 Jul 2017

BRIEF-Agile Therapeutics announces FDA acceptance of NDA resubmission of Twirla

* Agile Therapeutics announces FDA acceptance of the NDA resubmission of Twirla®

27 Jul 2017

BRIEF-Agile therapeutics resubmits new drug application for transdermal contraceptive patch

* Agile therapeutics resubmits new drug application (NDA) for its transdermal contraceptive patch, Twirla®

27 Jun 2017

Earnings vs. Estimates